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Abstract
Introduction: Diffuse large B-cell lymphoma is a diffuse proliferation of large neoplastic B lymphoid cells with a
nuclear size equal to or exceeding the normal macrophage nuclei. We report a case of a clear cell variant of
diffuse large B-cell lymphoma involving a lymph node in the neck, which was clinically suspected of being
metastatic carcinoma.
Case presentation: A 39-year-old Caucasian ethnic Albanian man from Kosovo presented with a rapidly enlarging
lymph node in his neck, but he also disclosed B symptoms and fatigue. A cytological aspirate of the lymph node
revealed pleomorphic features. Our patient underwent a cervical lymph node biopsy (large excision). The mass was
homogeneously fish-flesh, pale white tissue replacing almost the whole structure of the lymph node. The lymph
node biopsy showed a partial alveolar growth pattern, which raised clinical suspicion that it was an epithelial
neoplasm. With regard to morphological and phenotypic features, we discovered large nodules in diffuse areas,
comprising large cells with slightly irregular nuclei and clear cytoplasm admixed with a few mononuclear cells. In
these areas, there was high mitotic activity, and in some areas there were macrophages with tangible bodies.
Staining for cytokeratins was negative. These areas had the following phenotypes: cluster designation marker 20
(CD20) positive, B-cell lymphoma (Bcl)-2-positive, Bcl-6
-, CD5
-, CD3
-, CD21
+ (in alveolar patterns), prostate-specific
antigen-negative, human melanoma black marker 45-negative, melanoma marker-negative, cytokeratin-7-negative
and multiple myeloma marker 1-positive in about 30% of cells, and exhibited a high proliferation index marker (Ki-
67, 80%).
Conclusion: According to the immunohistochemical findings, we concluded that this patient has a clear cell
variant of diffuse large B-cell lymphoma of activated cell type, post-germinal center cell origin. Our patient is
undergoing R-CHOP chemotherapy treatment.
Introduction
Diffuse large B-cell lymphoma (DLBCL) displays striking
heterogeneity at the clinical, genetic and molecular levels
[1]. DLBCL is the most common type of lymphoid tumor
worldwide. This category was included in both the
Revised European American Lymphoma (REAL) [2] clas-
sification system and the World Health Organization
(WHO) classifications of 2001 [3] and 2008 [4], with the
aim of lumping together all malignant lymphomas char-
acterized by the large size of the neoplastic cells of B-cell
derivation as well as by an aggressive clinical presentation
and the need for highly effective chemotherapy regimens
[5]. These tumors are detected as primary or secondary
forms at both the nodal and extra-nodal levels in
i m m u n e - c o m p e t e n th o s t sa sw e l la si np a t i e n t sw i t hd i f -
ferent types of immune-suppression. They display signifi-
cant variability in terms of cell morphology and clinical
findings, which justifies the identification of variants and
subtypes [5]. DLBCL is a diffuse proliferation of large
neoplastic B lymphoid cells with a nuclear size equal to
or exceeding that of normal macrophage nuclei. How-
ever, even on the basis of simple histological examina-
tion, considerable heterogeneity can be seen, and several
morphological variants have been described [3].
Immunophenotype, tissue microarray and molecular
studies underline the extreme heterogeneity of DLBCLs
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basis of the identification of different pathogenic path-
ways; this might have much greater relevance than pure
morphology for precise prognostic previsions and the
adoption of ad hoc therapies. Recent reports regarding
the pathobiology of DLBCLs are reviewed in light of
these authors’ experience, with the aim of contributing
to the existing debate on the topic [6,7].
DLBCL is the most common type of non-Hodgkin’s
lymphoma. The International Prognostic Index is useful in
predicting the outcomes of patients with DLBCL. The dis-
covery of specific genetic alterations and the assessment of
protein expression led to the identification of multiple,
novel, single molecular markers capable of predicting the
outcomes of patients with DLBCL independently of clini-
cal variables [8]. However, much confusion exists in the
literature regarding the importance of different prognostic
biomarkers and their applicability in routine practice
[9-14].
Case presentation
A 39-year-old Caucasian ethnic Albanian man from
Kosovo presented with rapidly enlarging lymph nodes in
his neck, but he also disclosed B symptoms and fatigue.
A peripheral blood examination revealed no pathological
changes. A cytological aspirate of his lymph node dis-
closed pleomorphic features. Our patient underwent a
cervical lymph node biopsy (large excision).
According to the first biopsy findings, based on hema-
toxylin and eosin-stained slides created by co-authors (SL
and LSH), the diagnosis was suspected of being a cervical
lymph node metastatic carcinoma; therefore, it was inves-
tigated for primary carcinoma, which was not identified.
Clinically and radiographically, the mediastinum was
clear. This case has been reviewed by the authors (SMK
and GP), who arrived at the final diagnosis of a clear cell
variant of DLBCL.
Macroscopic findings
The mass was homogeneously fish-flesh, pale white tis-
sue replacing almost the whole structure of the lymph
node. There was no other tumor mass in the body or in
the mediastinum.
Histological and phenotypic findings
The lymph node biopsy showed a partially alveolar growth
pattern, marked sclerosis and hyalinization (Figure 1),
which raised clinical suspicions of an epithelial neoplasm.
The morphological and phenotypic features comprised
large nodules in diffuse areas, composed of large cells with
slightly irregular nuclei and clear cytoplasm admixed with
a few mononuclear cells, as well as sheets of large cells
with abundant pale cytoplasm separated by collagenous
fibrosis. The nuclei were round (centroblast-like) or
sometimes multi-lobulated (Figure 2). These areas dis-
played high mitotic activity, and some areas contained
macrophages with tangible bodies. Staining for cytokera-
tins (CK) was negative. These areas disclosed the following
phenotype: cluster designation marker 20 (CD20)
expressed strong positivity (Figure 3), B-cell lymphoma
(Bcl)-2 expressed cytoplasmic staining (Figure 4), Bcl-6
-,
CD5
-,C D 3
-,C D 2 1
+ (in alveolar patterns), prostate-specific
antigen-negative (PSA
-), human melanoma black marker
45-negative (HMB45
-), melanoma marker-negative
(Melan
-), CK7
- and multiple myeloma marker 1-positive
(MUM1
+)i na b o u t3 0 %o fc e l l sa n dK i - 6 7e x p r e s s e da
high proliferation index of 80%. (Figure 5).
On the basis of the histological examination, the dif-
ferential diagnosis of the tumor needed to include other
Figure 2 Sheets of large cells with abundant pale cytoplasm
separated by collagenous fibrosis. Nuclei are round (centroblast-
like) or sometimes multi-lobulated (hematoxylin and eosin stain;
original magnification, × 40).
Figure 1 Marked sclerosis and hyalinization in diffuse large B-
cell lymphoma (hematoxylin and eosin stain; original
magnification, × 20).
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could be observed. Our first thought was the possibility
of primary mediastinal large B-cell lymphoma (PMBCL),
but clinically no tumor mass was found in the mediasti-
num. Radiography of the mediastinum did not show any
pathological change.
We also considered possible metastases from prostate
carcinoma or malignant melanoma, as well as mesench-
ymal large-cell neoplasms or undifferentiated large-cell
carcinoma. Therefore, we performed immunohistochem-
istry (IHC) to define the histological type of the tumor.
T h et e c h n i q u eu s e di no u rc a s ew a st h ea v i d i n - b i o t i n
complex (ABC) as a standard IHC method.
The IHC results excluded clinical suspicions of a
metastatic tumor. The differential diagnosis following
the first round of IHC included uncommon, undifferen-
tiated large-cell carcinoma, malignant melanoma,
undifferentiated mesenchymal large-cell neoplasms and
prostate carcinoma.
In the second round of IHC, we considered the possi-
bility of DLBCL. (The morphological variants are cen-
troblastic, immunoblastic, T-cell- and histiocyte-rich,
anaplastic, plasmablastic, DLBCL-anaplastic lymphoma
kinase-positive and PMBCL.) Our final diagnosis was of
a clear cell variant of DLBCL.
Discussion
All large B-cell lymphomas have been lumped together
into two categories in the REAL classification published
in 1994 [2]: DLBCL and PMBCL. In the WHO classifica-
tion of 2001 [3], and even in the new WHO classification
of 2008 [4], the most convincing variants of DLBCL were
therefore separated based on the belief that these variants
represent distinct clinico-pathologic entities [15].
Our case had to be differentiated from other variants
of DLBCL, such as T-cell histiocyte-rich large B-cell
lymphoma (TCHRLBCL), which shows CD20
+,C D 3 0
-,
CD15
-, almost no small CD20
+ or immunoglobulin D-
positive (IgD
+) B-cells and often more CD8
+ than CD4
+
T-cells in the background. We also had to differentiate
our case from PMBCL.
Employing various immunohistochemical antibodies,
such as CD10, CD138, anti-Bcl-2, anti-Bcl-6, MUM1
and anti-p53, several groups have tried to sub-classify
DLBCL into the germinal center B-cell-like DLBCL
(GCB-DLBCL) and activated B-cell-like DLBCL (ABC-
DLBCL) sub-groups, with comparable differences in
clinical behavior [16]. Alizadeh et al. [17] identified two
molecularly distinct forms of DLBCL which had gene
expression patterns indicative of different stages of B-
cell differentiation. One type expressed genes character-
istic of GCB-DLCBL, and the second type expressed
Figure 3 CD20
+ expressed strong positivity (CD 20 stain;
original magnification, × 40).
Figure 4 Bcl-2
+ expressed cytoplasmic staining (Bcl-2 stain;
original magnification, × 40)
Figure 5 Ki-67
+ expressed a high proliferation index (Ki-67
stain, 80%, × 20).
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ipheral blood B-cells (ABC-DLBCL). Patients with GCB-
DLCBL had significantly better overall survival than
those with ABC-DLBCL [18,19].
The patients with GCB-DLCBL had better prognosis
than the non-GCB subtype. Both ABC-DLBCL and
GCB-DLBCL show a significant improvement of overall
survival after rituximab, cyclophosphamide, doxorubicin,
Oncovin (vincristine sulfate) and prednisolone (R-
CHOP) chemotherapy treatment [20]. Our patient with
ABC-DLBCL underwent R-CHOP treatment and is
alive.
Over-expression of Bcl-6 protein caused by Bcl-6 gene
rearrangement may play some important roles in the
development and/or progression of a subset of DLBCL
[21]. The group with pattern B (ABC-DLBCL) demon-
strated more frequent expression of Ki-67, cyclin D3
and geminin, and showed higher proliferation activity
than the group with pattern A (GCB-DLBCL). These
findings suggest that high proliferation activity of
tumors with pattern B may be associated with aggressive
tumor behavior and poor clinical outcomes in patients
with DLBCL [22].
Commonly observed genetic abnormalities that likely
contribute to pathogenesis include translocation of BCL-
6, BCL-2, c-Myc and FAS (CD95) mutations and aber-
rant somatic hyper-mutation. Additional novel therapies
under investigation include those targeting BCL6 and
BCL2. Also, the development of novel monoclonal anti-
body-based therapies is underway.
PMBCL has been thought of as a special subtype of
DLBCL. Its distinct clinical presentation in younger
patients, with a female predominance, has led to the sus-
picion that it constitutes a unique entity. However, a reli-
able distinction from DLBCL has remained elusive [23].
The subdivision of grade 3 follicular lymphoma (FL3)
into the cytologic subtypes of 3a, 3b, and follicular large
cleaved cell lymphoma (FLC) does not appear to be clini-
cally important. However, to prevent its misclassification
as a low-grade follicular lymphoma, FLC should be recog-
nized and considered as a morphologic subtype of FL3 for
clinical purposes. Finally, patients with FL3 with a signifi-
cant diffuse component (>50%) have an inferior survival
that is similar to the survival of those with DLBCL [24].
In children, the Burkitt lymphoma (BL) and DLBCL
subtypes probably do not differ clinically, although the
differential diagnosis between BL and DLBCL may theo-
retically appear clear-cut. In adults, daily practice shows
the existence of cases that have immuno-phenotypic and
cytogenetic morphological features that are intermediate
between DLBCL and BL, and thus cannot be classified
into either of these categories with certainty [25].
The overlap between BL and DLBCL has been dis-
cussed, including mediastinal “gray zone” lymphoma
and other lymphomas with atypical immuno-pheno-
types. These overlapping lymphoma types include the
gray zone around nodular lymphocyte-predominant
Hodgkin’s lymphoma (NLPHL), TCHRLBCL, classical
Hodgkin’s lymphoma (cHL), Epstein-Barr virus-positive
lymphomas, lymphomas occurring in patients with
human immunodeficiency virus, post-transplant lym-
pho-proliferative disorder-related B-cell lympho-prolif-
erations and DLBCLs with an unusual immuno-
phenotype. It has become clear that the “double-hit”
cases (the combination of a c-Myc breakpoint with
mostly BCL2 breakpoints and other recurrent chromo-
somal breakpoints), often with distinct morphological
features of BL, should fall into a novel category of “B-
cell lymphoma, unclassifiable, with features intermediate
between DLBCL and BL.”
The main issue addressed during the workshop of the
XIV meeting of the European Association for Hemato-
pathology was to define criteria to reliably distinguish
entities such as NLPHL, TCHRLBCL and the gray zones
between cHL and DLBCL, mainly, TCHRLBCL in the
lymph nodes [26].
Conclusion
“Gray zone lymphoma”, a term which has been used to
denote a group of various types of lymphomas with
overlapping histological, biological and clinical features,
remains a diagnostic problem for pathologists. On the
basis of our IHC findings, we have concluded that the
diagnosis in the present case is a clear cell variant of
DLBCL of activated cell type, post-germinal center cell
origin. Our patient is alive and undergoing R-CHOP
chemotherapy treatment. Increased molecular under-
standing of the heterogeneous subsets within DLBCL
will likely improve the current treatment of patients
with DLBCL by identifying rational therapeutic targets
in specific disease subtypes.
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